Patents by Inventor Steven Marc Massey

Steven Marc Massey has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • DISUBSTITUTED PYRAZOLE COMPOUNDS
    Publication number: 20220017496
    Abstract: The present invention provides a compound of Formula I. or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.
    Type: Application
    Filed: September 17, 2021
    Publication date: January 20, 2022
    Inventors: David Andrew COATES, Timothy Barrett DURHAM, Richard Duane JOHNSTON, Steven Marc MASSEY, Patrick Gianpietro SPINAZZE, Douglas Richard STACK, James Lee TOTH
  • Disubstituted pyrazole compounds
    Patent number: 11124500
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.
    Type: Grant
    Filed: June 16, 2020
    Date of Patent: September 21, 2021
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Timothy Barrett Durham, Richard Duane Johnston, Steven Marc Massey, Patrick Gianpietro Spinazze, Douglas Richard Stack, James Lee Toth
  • DISUBSTITUTED PYRAZOLE COMPOUNDS
    Publication number: 20200392118
    Abstract: The present invention provides a compound of Formula I or a pharmaceutically acceptable salt thereof, and the use of compounds of Formula I for treating metabolic conditions, such as type 2 diabetes mellitus, heart failure, diabetic kidney disease, and non-alcoholic steatohepatitis.
    Type: Application
    Filed: June 16, 2020
    Publication date: December 17, 2020
    Inventors: David Andrew COATES, Timothy Barrett DURHAM, Richard Duane JOHNSTON, Steven Marc MASSEY, Patrick Gianpietro SPINAZZE, Douglas Richard STACK, James Lee TOTH
  • CGRP receptor antagonists
    Patent number: 9708297
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: July 18, 2017
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Kevin Charles Fortner, Steven Marc Massey, Jason Kenneth Myers, Antonio Navarro, Miles Goodman Siegel, Russell Dean Stucky
  • CGRP receptor antagonists
    Patent number: 9637495
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Grant
    Filed: August 5, 2016
    Date of Patent: May 2, 2017
    Assignee: Eli Lilly and Company
    Inventors: David Andrew Coates, Kevin Charles Fortner, Richard Duane Johnston, Steven Marc Massey, Jason Kenneth Myers, Qing Shi, Miles Goodman Siegel
  • CGRP RECEPTOR ANTAGONISTS
    Publication number: 20170044138
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 16, 2017
    Inventors: David Andrew Coates, Kevin Charles Fortner, Steven Marc Massey, Jason Kenneth Myers, Antonio Navarro, Miles Goodman Siegel, Russell Dean Stucky
  • CGRP RECEPTOR ANTAGONISTS
    Publication number: 20170044163
    Abstract: The present invention provides a compound of Formula II: or a pharmaceutically acceptable salt thereof.
    Type: Application
    Filed: August 5, 2016
    Publication date: February 16, 2017
    Inventors: David Andrew Coates, Kevin Charles Fortner, Richard Duane Johnston, Steven Marc Massey, Jason Kenneth Myers, Qing Shi, Miles Goodman Siegel
  • Pyridyl derivatives and their use as mGlu5 antagonists
    Patent number: 7915424
    Abstract: The present invention is directed toward pyridyl derivatives of formula (I) as antagonists of the mGlu5 receptor.
    Type: Grant
    Filed: March 9, 2005
    Date of Patent: March 29, 2011
    Assignee: Eli Lilly and Company
    Inventors: Francisco Javier Agejas-Chicharro, Bruce Anthony Dressman, Jose Antonio Martinez Perez, James Allen Monn, Mohammad Sadegh Zia-Ebrahimi, Sonia Gutierrez Sanfeliciano, Steven Marc Massey, Steven Scott Henry
  • Pyridyl Derivatives and Their Use as Mglu5 Antagonists
    Publication number: 20080194647
    Abstract: The present invention is directed toward pyridyl derivatives of formula (I) as antagonists of the mGlu5 receptor.
    Type: Application
    Filed: March 9, 2005
    Publication date: August 14, 2008
    Applicant: ELI LILLY AND COMPANY
    Inventors: Francisco Javier Agejas-Chicharro, Anthony Bruce Dressman, Sonia Gutierrez Sanfeliciano, Steven Scott Henry, Jose Antonio Martinez Perez, Steven Marc Massey, James Allen Monn, Mohammad Sadegh Zia-Ebrahimi
  • Prodrugs of excitatory amino acids
    Publication number: 20040248963
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs of formula (I) wherein the residues R11, R12 and R13 are as defined in claim 1. The invention further relates to processes for the preparation of the compounds of formula (I), and to pharmaceutical compositions for the treatment of neurological and psychiatric disorders comprising said compounds.
    Type: Application
    Filed: April 30, 2004
    Publication date: December 9, 2004
    Inventors: Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Mark Francis Herin, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Maria Angeles Martinez-Grau, Steven Marc Massey, James Allen Monn, Carlos Montero Salgado, Concepcion Pedregal-Tercero, Matthew John Valli
  • Prodrugs of excitatory amino acids
    Publication number: 20040176459
    Abstract: This invention relates to synthetic excitatory amino acid prodrugs and processes for their preparation. The invention further relates to methods of using, and pharmaceutical compositions comprising, the compounds for the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: December 10, 2003
    Publication date: September 9, 2004
    Inventors: Ana Belen Bueno Melendo, Alfonso De Dios, Carmen Dominguez-Fernandez, Luisa Maria Martin-Cabrejas, Jose Alfredo Martin, Carlos Montero Salgado, Concepcion Pedregal-Tercero, Rafael Ferritto Crespo, Marc Francis Herin, Maria Angeles Martinez-Grau, Steven Marc Massey, James Allen Monn, Matthew John Valli
  • Synthetic excitatory amino acids
    Publication number: 20040116489
    Abstract: The present invention provides novel compounds that affect certain excitatory amino acid receptors, and are useful in the treatment of neurological disorders and psychiatric disorders.
    Type: Application
    Filed: December 8, 2003
    Publication date: June 17, 2004
    Inventors: Steven Marc Massey, James Allen Monn, Matthew John Valli, Lourdes Prieto
  • Hydantoin derivatives
    Patent number: 6268507
    Abstract: Compounds of the formula in which R1 and R2 are as defined in the specification, and non-toxic metabolically labile ester and amides thereof are useful as modulators of metabotropic glutamate receptor function.
    Type: Grant
    Filed: August 11, 2000
    Date of Patent: July 31, 2001
    Assignee: Eli Lilly and Company
    Inventors: Steven Marc Massey, James Allen Monn, Matthew John Valli
  • Excitatory amino acid receptor modulators
    Patent number: 6160009
    Abstract: Compounds of the formula ##STR1## in which R.sup.1 and R.sup.2 are as defined in the specification, and non-toxic metabolically labile ester and amides thereof are useful as modulators of metabotropic glutamate receptor function.
    Type: Grant
    Filed: May 28, 1999
    Date of Patent: December 12, 2000
    Assignee: Eli Lilly and Company
    Inventors: Steven Marc Massey, James Allen Monn, Matthew John Valli
  • Excitatory amino acid receptor modulators
    Patent number: 5958960
    Abstract: Compounds of the formula ##STR1## in which R.sup.1 and R.sup.2 are as defined in the specification, and non-toxic metabolically labile ester and amides thereof are useful as modulators of metabotropic glutamate receptor function.
    Type: Grant
    Filed: May 13, 1998
    Date of Patent: September 28, 1999
    Assignee: Eli Lilly and Company
    Inventors: Steven Marc Massey, James Allen Monn, Matthew John Valli
  • 3-substituted Bicyclo?3.1.0!hexane-6-carboxylic acids
    Patent number: 5916920
    Abstract: Compounds of the formula ##STR1## in which X represents a bond, S, O or NR.sup.a ; and R is as defined in the specification are useful as modulators of metabotropic glutamate receptor function.
    Type: Grant
    Filed: November 14, 1996
    Date of Patent: June 29, 1999
    Assignee: Eli Lilly and Company
    Inventors: Carmen Dominguez Fernandez, David Reed Helton, Steven Marc Massey, James Allen Monn
  • Excitatory amino acid derivatives
    Patent number: 5688826
    Abstract: Compounds for formula I ##STR1## in which X represents O, NR.sup.a, S, SO or SO.sub.2 and R is as defined in the specification; and non-toxic metabolically labile esters or amides thereof; and pharmaceutically acceptable salts thereof are useful as modulators of metabotropic glutamate receptor function.
    Type: Grant
    Filed: November 14, 1996
    Date of Patent: November 18, 1997
    Assignee: Eli Lilly and Company
    Inventors: Steven Marc Massey, James Allen Monn, Matthew John Valli